NAPc2

NAPc2

Nematode Anticoagulant Protein c2 Hematology An inhibitor of the enzymatic complex factor VIIa/tissue factor that initiates coagulation, possibly of use in the future for managing DVT. See Deep vein thrombosis.
References in periodicals archive ?
NASDAQ:CVAS) presented results of preclinical studies on NAPc2 Wednesday at the 69th Scientific Sessions of the American Heart Association in New Orleans.
The studies indicate that NAPc2, an inhibitor of the enzymatic complex Factor VIIa/Tissue Factor that initiates blood coagulation, demonstrates significant anticoagulant properties.
These data may indicate that the inhibition of Factor VIIa/Tissue Factor with NAPc2 is a viable strategy for treatment of both acute arterial and venous thrombosis.
In a porcine model of thrombosis, a recombinant form of NAPc2 (rNAPc2) was highly effective following intravenous administration in preventing acute platelet dependent arterial thrombosis in coronary arteries, with no adverse side effects.
for the manufacture of clinical supplies of NAPc2 in preparation for human trials, expected to begin in early 1997.
Vlasuk also presented preclinical data on NAPc2, a protein anticoagulant being developed for acute thrombotic diseases, with an initial emphasis on venous thrombosis.
In various animal models of thrombosis, including venous and arterial thrombosis, a recombinant form of NAPc2 demonstrated efficacy advantages over a commonly used anticoagulant, following both intravenous and subcutaneous administration.
Corvas also announced that it has signed an agreement with Immunex for the manufacture of clinical supplies of NAPc2 for trials which Corvas intends to conduct in early 1997.
Based on these findings, and on a significant body of unpublished data, Corvas has selected a lead candidate, NAPc2, for development as a potential antithrombotic drug for the treatment of major acute cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, unstable angina and heart attack.
Corvas is proceeding with active preclinical development of NAPc2 in preparation for human clinical trials to begin in early 1997.
Pharmacology studies on NAPc2 are scheduled to be conducted at the Cleveland Clinic.
A third form -- NAPc2 -- inhibits the enzymatic complex of Factor VIIa and tissue factor (TF) by a unique mechanism of action.